<?xml version='1.0' encoding='utf-8'?>
<document id="23374617"><sentence text="Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents." /><sentence text="To describe 12-month rates and patterns of coprescription of drugs that potentially create drug-drug interactions (DDIs) through shared metabolic or transport pathways for 9 enzyme-targeted kinase inhibitor oral antineoplastic drugs (OADs)" /><sentence text="" /><sentence text="We used a deidentified pharmacy claims database identifying patients prescribed dasatinib, erlotinib, everolimus, imatinib, lapatinib, nilotinib, pazopanib, sorafenib, or sunitinib between January 1, 2008, and May 31, 2010"><entity charOffset="80-89" id="DDI-PubMed.23374617.s4.e0" text="dasatinib" /><entity charOffset="91-100" id="DDI-PubMed.23374617.s4.e1" text="erlotinib" /><entity charOffset="102-112" id="DDI-PubMed.23374617.s4.e2" text="everolimus" /><entity charOffset="114-122" id="DDI-PubMed.23374617.s4.e3" text="imatinib" /><entity charOffset="124-133" id="DDI-PubMed.23374617.s4.e4" text="lapatinib" /><entity charOffset="135-144" id="DDI-PubMed.23374617.s4.e5" text="nilotinib" /><entity charOffset="146-155" id="DDI-PubMed.23374617.s4.e6" text="pazopanib" /><entity charOffset="157-166" id="DDI-PubMed.23374617.s4.e7" text="sorafenib" /><entity charOffset="171-180" id="DDI-PubMed.23374617.s4.e8" text="sunitinib" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e0" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e1" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e2" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e3" e2="DDI-PubMed.23374617.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e3" e2="DDI-PubMed.23374617.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e3" e2="DDI-PubMed.23374617.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e3" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e3" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e3" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e4" e2="DDI-PubMed.23374617.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e4" e2="DDI-PubMed.23374617.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e4" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e4" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e4" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e5" e2="DDI-PubMed.23374617.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e5" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e5" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e5" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e6" e2="DDI-PubMed.23374617.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e6" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e6" e2="DDI-PubMed.23374617.s4.e8" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e7" e2="DDI-PubMed.23374617.s4.e7" /><pair ddi="false" e1="DDI-PubMed.23374617.s4.e7" e2="DDI-PubMed.23374617.s4.e8" /></sentence><sentence text=" Coprescribing was 1 or more overlapping days of supply between the OAD and potential DDI drugs during the 12-month period beginning on the OAD index date" /><sentence text=" Product labels identified the cytochrome P450 metabolic enzymes used and whether P-glycoprotein was used by the OADs" /><sentence text=" Drugs that induce and/or inhibit these pathways were identified from the label and online resources" /><sentence text="" /><sentence text="Sample sizes ranged from 96 (pazopanib group) to 4617 (imatinib group)"><entity charOffset="29-38" id="DDI-PubMed.23374617.s9.e0" text="pazopanib" /><entity charOffset="55-63" id="DDI-PubMed.23374617.s9.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.23374617.s9.e0" e2="DDI-PubMed.23374617.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23374617.s9.e0" e2="DDI-PubMed.23374617.s9.e1" /></sentence><sentence text=" Coprescribing rates with drugs that may decrease OAD effectiveness were 359/1546 (23%) (sunitinib group) to 1851/3263 (57%) (erlotinib group)"><entity charOffset="89-98" id="DDI-PubMed.23374617.s10.e0" text="sunitinib" /><entity charOffset="126-135" id="DDI-PubMed.23374617.s10.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.23374617.s10.e0" e2="DDI-PubMed.23374617.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23374617.s10.e0" e2="DDI-PubMed.23374617.s10.e1" /></sentence><sentence text=" Coprescribing rates with drugs that may increase OAD toxicity were 364/1546 (24%) (sunitinib group) to 71/96 (74%) (pazopanib group)"><entity charOffset="84-93" id="DDI-PubMed.23374617.s11.e0" text="sunitinib" /><entity charOffset="117-126" id="DDI-PubMed.23374617.s11.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.23374617.s11.e0" e2="DDI-PubMed.23374617.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23374617.s11.e0" e2="DDI-PubMed.23374617.s11.e1" /></sentence><sentence text=" Patients coprescribed DDI drugs had a median of 1 to 4 more medications present on the OAD index date than those not coprescribed a DDI drug" /><sentence text=" Most groups coprescribed DDI drugs had a median of 180 or more OAD days of supply during follow-up" /><sentence text=" The proportion of OAD days of supply with overlapping days of DDI drugs ranged from 7% to 85%" /><sentence text=" Generally, oncologists prescribed the OAD and nononcologists the DDI drug" /><sentence text="" /><sentence text="Coprescription of drugs that induce or inhibit metabolic pathways used by enzyme-targeted kinase inhibitor OADs is high" /><sentence text=" The clinical consequences need further study" /><sentence text="" /></document>